LogoFDA 510(k) Search
Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K042732
    Device Name
    ARCHITECT CA 15-3 ASSAY
    Manufacturer
    FUJIREBIO DIAGNOSTICS, INC.
    Date Cleared
    2004-12-22

    (82 days)

    Product Code
    MOI,JIT,JJX
    Regulation Number
    866.6010
    Type
    Traditional
    Panel
    Immunology
    Reference & Predicate Devices
    K963926
    Why did this record match?
    Device Name :

    ARCHITECT CA 15-3 ASSAY

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The ARCHITECT CA 15-3 assay is a Chemiluminescent Microparticle Immunoassay (CMIA) for the quantitative determination of DF3 defined antigen in human serum and plasma on the ARCHITECT i System. The ARCHITECT CA 15-3 assay is to be used as an aid in the management of Stage II and Stage III breast cancer patients. Serial testing for patient CA 15-3 assay values should be used in conjunction with other clinical methods for monitoring breast cancer.

    Device Description

    The ARCHITECT CA 15-3 assay is a two-step immunoassay to determine the presence of DF3 reactive determinants in human serum or plasma, using Chemiluminescent Microparticle Immunoassay (CMIA) technology with flexible assay protocols, referred to as Chemiflex™. In the first step, sample, wash buffer and 115D8 coated paramagnetic microparticles are combined. DF3 reactive determinants present in the sample bind to the 115D8 coated microparticles. After washing, DF3 acridinium-labeled conjugate is added in the second step. Pre-Trigger and Trigger Solutions are then added to the reaction mixture; the resulting chemiluminescent reaction is measured as relative light units (RLUs). A direct relationship exists between the amount of DF3 reactive determinants in the sample and the RLUs detected by the ARCHITECT i optical system.

    AI/ML Overview

    Acceptance Criteria and Device Performance Study for ARCHITECT® CA 15-3® Assay

    This document summarizes the acceptance criteria and the study performed to demonstrate that the ARCHITECT® CA 15-3® Assay meets these criteria, based on the provided 510(k) summary.

    1. Table of Acceptance Criteria and Reported Device Performance

    The provided document details various performance characteristics, which serve as the acceptance criteria for the device. The reported performance for the ARCHITECT CA 15-3 Assay is compared against these criteria.

    Performance CharacteristicAcceptance Criteria (Implied)Reported Device Performance
    ReproducibilityTotal precision %CV ≤ 8%The total precision %CV of the ARCHITECT® CA 125 II™ assay was determined to be less than or equal to 8%. (Note: The document mentions "CA 125 II™ assay" here, but the 510(k) is for CA 15-3, implying this criterion is general for ARCHITECT assays or a typo. Assuming it applies to CA 15-3.)
    Method ComparisonHigh correlation with predicate device (AxSYM CA 15-3 assay)Passing-Bablok linear regression analysis comparing the ARCHITECT CA 15-3 assay to the AxSYM CA 15-3 assay yielded a correlation coefficient of 0.980, a slope of 0.94 (99% CI: 0.92, 0.97), and Y-axis intercept of -0.3 U/mL (99% CI: -0.9, 0.0).
    Reference RangesEstablishment of normal ranges in apparently healthy populations.In 396 normal individual specimens, 99.0% of healthy female subjects had CA 15-3 assay values at or below 31.3 U/mL (mean = 13.0, SD = 7.0). Similar distributions were provided for pre-menopausal females (99%
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1